bluebird bio, Inc. (NASDAQ:BLUE) announced today that data from its gene therapy programs for sickle cell disease (SCD), transfusion-dependent β-thalassemia (TDT) and its cell therapy program for relapsed and refractory multiple myeloma (RRMM) will be presented during the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress.
New data from the company’s Phase 1/2 HGB-206 study of LentiGlobin™ gene therapy for SCD will be presented, including updated data from patients in Group C.
bluebird bio will also present data from its ongoing clinical studies of betibeglogene autotemcel (formerly LentiGlobin™ gene therapy for β-thalassemia), including the Phase 3 Northstar-2 (HGB-207) study in patients who do not have a β0/β0 genotype and the Phase 3 Northstar-3 (HGB-212) study in patients who have β0/β0, β0/β+IVS-I-110, or β+IVS-I-110/β+IVS-I-110 genotypes.
Data from studies of idecabtagene vicleucel (ide-cel; bb2121), the company’s anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy in development with Bristol Myers Squibb, will be presented, including an encore presentation of results from the pivotal Phase 2 KarMMa study.
Sickle Cell Disease Data at EHA25
Oral Presentation: Outcomes in patients treated with LentiGlobin for sickle cell disease (SCD) gene therapy: Updated results from the Phase 1/2 HGB-206 group C study
Presenting Author: Julie Kanter, M.D., University of Alabama at Birmingham, Birmingham, Ala.
Transfusion-Dependent β-Thalassemia Data at EHA25
Oral Presentation: Improvement in erythropoiesis in patients with transfusion-dependent β-thalassemia following treatment with betibeglogene autotemcel (LentiGlobin for β-thalassemia) in the Phase 3 HGB-207 study
Presenting Author: John B. Porter, MA, M.D., FRCP, FRCPath, University College London Hospital, London, UK
Poster: Betibeglogene autotemcel (LentiGlobin) in patients with transfusion-dependent β-thalassemia and β0/β0, β+IVS-I-110/β+IVS-I-110, or β0/β+IVS-I-110 genotypes: Updated results from the HGB-212 study
Presenting Author: Evangelia Yannaki, M.D., George Papanicolaou Hospital, Thessaloniki, Greece
Multiple Myeloma Data at EHA25
Oral Presentation: Phase II KarMMa study: Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T cell therapy, in patients with relapsed and refractory multiple myeloma
Presenting Author: Jesus San-Miguel, M.D., Ph.D., Clinica Universidad de Navarra, Navarra, Spain
Poster: Quality of life in patients with relapsed and refractory multiple myeloma treated with the BCMA-targeted CAR T cell therapy Idecabtagene vicleucel (ide-cel; bb2121): results from the KarMMa Trial
Presenting Author: Michel Delforge, M.D., Ph.D., Leuven University College, Brussels, Belgium
Poster: Matching-adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel from the KarMMa study vs selinexor PLUS dexamethasone (STORM part 2) and belantamab mafodotin (DREAMM-2)
Presenting Author: Paula Rodriguez-Otero, M.D., Clinica Universidad de Navarra, Navarra, Spain
Poster: Baseline and postinfusion pharmcodynamic biomarkers of safety and efficacy in patients treated with idecabtagene vicleucel (ide-cel; bb2121) in the KarMMa study
Presenting Author: Justine Dell’Aringa, Bristol Myers Squibb, Seattle, Wash.
Poster: Correlation of tumor BCMA expression with response and acquired resistance to idecabtagene vicleucel in the KarMMa study in relapsed and refractory multiple myeloma
Presenting Author: Nathan Martin, Bristol Myers Squibb, Seattle, Wash.
Abstracts outlining bluebird bio’s accepted data at the EHA25 Virtual Congress have been made available on the EHA25 conference website. On Friday, June 12 at 8:30 AM CEST, the embargo will lift for poster and oral presentations accepted for EHA25.